Please find the attached Outcome of Board Meeting
Awaiting price reaction for this filing.
Cresanto Global Ltd (formerly Raymed Labs) reported deeply concerning FY26 results with a net loss of Rs 43.03 lakhs, nearly double the previous year's loss of Rs 18.05 lakhs. Total income collapsed to just Rs 7.56 lakhs from Rs 52.59 lakhs in FY25—a revenue decline of 85.6%. The company has negative total equity of Rs 301.81 lakhs, meaning liabilities exceed assets significantly. Operating cash flows remained deeply negative at Rs 42.91 lakhs. Despite the grim financials, auditors K T P S & Co. issued an unmodified (clean) opinion. The company has nominal cash of only Rs 0.62 lakhs against borrowings of Rs 280.64 lakhs.
The stock faces extreme risk due to massive revenue shrinkage, widening losses, negative equity, and negative operating cash flows. Despite a clean audit opinion, the balance sheet insolvency (negative equity) raises serious questions about the company's ability to continue operations without major capital infusion or restructuring.